Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies.…
| Periodo | 2020-04 |
|---|---|
| Real | $-0.45 |
| Estimado | $-1.05 |
| Sorpresa | +57.1% |
| Métrica | MARI.VI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | -55.9% | -34.4% | -21.5% |
| Net Margin | -74.0% | -32.5% | -41.5% |
| FCF Margin | — | -12.6% | — |
| ROE | — | -39.2% | — |
| ROA | -46.5% | -30.9% | -15.6% |
| Current Ratio | 0.74 | 2.73 | -1.99 |
| Debt / Equity | -1.46 | 0.28 | -1.74 |
| Tendencia (Piotroski) | FY23 | FY22 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -46.5% | — |
| ✗Flujo de caja operativo positivo | −€5M | −€5M |
| ✗Rentabilidad sobre activos al alza | -46.5% | -28.7% |
| ✓Caja operativa/activos supera al ROA | -31.0% | ROA -46.5% |
| ✗Menos deuda a largo plazo | 101.6% | 90.6% |
| ✗Mejor liquidez (ratio corriente) | 0.74 | 2.40 |
| ✗Sin aumentar el nº de acciones | 0M | 0M |
| –Margen bruto al alza | — | — |
| ✓Rotación de activos al alza | 0.63 | 0.51 |
| Calidad del negocio | FY23 |
|---|---|
| ✗ROCE > 10 % | -103.4% |
| ✗Ventas > 5 %/año (3 años) | 4.2% |
| ✓Deuda neta/EBITDA < 3x | -4.3x |
Marinomed Biotech AG cotiza a 4.00 EUR y tiene una capitalización bursátil de €8M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud